Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $261.65 million. The enterprise value is $109.08 million.
| Market Cap | 261.65M |
| Enterprise Value | 109.08M |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 50.51 million shares outstanding. The number of shares has increased by 21.90% in one year.
| Shares Outstanding | 50.51M |
| Shares Change (YoY) | +21.90% |
| Shares Change (QoQ) | +5.56% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 80.52% |
| Float | 24.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 245.91 |
| Forward PS | 40.81 |
| PB Ratio | 1.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 102.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.30.
| Current Ratio | 4.82 |
| Quick Ratio | 4.80 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.10% and return on invested capital (ROIC) is -72.84%.
| Return on Equity (ROE) | -74.10% |
| Return on Assets (ROA) | -49.10% |
| Return on Capital (ROIC) | -72.84% |
| Revenue Per Employee | $8,185 |
| Profits Per Employee | -$1.04M |
| Employee Count | 130 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GLUE has paid $421,000 in taxes.
| Income Tax | 421,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.96% in the last 52 weeks. The beta is 1.54, so GLUE's price volatility has been higher than the market average.
| Beta (1Y) | 1.54 |
| 52-Week Price Change | -7.96% |
| 50-Day Moving Average | 6.26 |
| 200-Day Moving Average | 5.36 |
| Relative Strength Index (RSI) | 41.87 |
| Average Volume (30 Days) | 155,933 |
Short Selling Information
The latest short interest is 1.91 million, so 3.79% of the outstanding shares have been sold short.
| Short Interest | 1.91M |
| Short Previous Month | 1.87M |
| Short % of Shares Out | 3.79% |
| Short % of Float | 7.97% |
| Short Ratio (days to cover) | 15.58 |
Income Statement
In the last 12 months, GLUE had revenue of $1.06 million and -$135.28 million in losses. Loss per share was -$2.51.
| Revenue | 1.06M |
| Gross Profit | 1.06M |
| Operating Income | -144.00M |
| Pretax Income | -134.86M |
| Net Income | -135.28M |
| EBITDA | -127.89M |
| EBIT | -134.86M |
| Loss Per Share | -$2.51 |
Balance Sheet
The company has $197.76 million in cash and $45.18 million in debt, giving a net cash position of $152.57 million or $3.02 per share.
| Cash & Cash Equivalents | 197.76M |
| Total Debt | 45.18M |
| Net Cash | 152.57M |
| Net Cash Per Share | $3.02 |
| Equity / Book Value | 152.52M |
| Book Value Per Share | 3.02 |
| Working Capital | 157.74M |
Cash Flow
In the last 12 months, operating cash flow was -$58.56 million and capital expenditures -$11.18 million, giving a free cash flow of -$69.74 million.
| Operating Cash Flow | -58.56M |
| Capital Expenditures | -11.18M |
| Free Cash Flow | -69.74M |
| FCF Per Share | -$1.16 |
Margins
Gross margin is 100.00%, with operating and profit margins of -13,533.74% and -12,714.47%.
| Gross Margin | 100.00% |
| Operating Margin | -13,533.74% |
| Pretax Margin | -12,674.91% |
| Profit Margin | -12,714.47% |
| EBITDA Margin | -12,020.02% |
| EBIT Margin | -12,674.91% |
| FCF Margin | -6,554.79% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.90% |
| Shareholder Yield | -21.90% |
| Earnings Yield | -51.70% |
| FCF Yield | -26.65% |
Analyst Forecast
The average price target for GLUE is $11.00, which is 111.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.00 |
| Price Target Difference | 111.54% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of -1.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.67 |
| Piotroski F-Score | 2 |